Last reviewed · How we verify
NCT01493713: AVAMET
Correlation Between RECIST, Morphologic Response by CT- Histopathologic Response in Hepatic Metastasis Secondary to Colorectal Cancer
Phase 4 trial testing Evaluate the correlation of overall different objective response. in Colorectal Cancer in 83 participants. Completed in 18 December 2017.
8 December 2014
Quick facts
| Lead sponsor | Grupo Espanol Multidisciplinario del Cancer Digestivo |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 83 |
| Start date | 16 November 2011 |
| Primary completion | 8 December 2014 |
| Estimated completion | 18 December 2017 |
| Sites | 21 locations across Spain |
Drugs / interventions tested
- Evaluate the correlation of overall different objective response.
Conditions studied
- Colorectal Cancer — all drugs for Colorectal Cancer →
- Hepatic Metastasis — all drugs for Hepatic Metastasis →
Sponsor
Grupo Espanol Multidisciplinario del Cancer Digestivo — full company profile →
Who can join
18 and older, any sex, with Colorectal Cancer or Hepatic Metastasis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to to evaluate the correlation of overall objective response according to RECIST v1.1. criteria evaluated by conventional imaging techniques, morphologic response by CT, and histopathologic response in patients with resectable hepatic metastasis secondary to colorectal cancer treated with bevacizumab in combination with XELOX.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Neoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agents.
García-Alfonso P, Ferrer A, Gil S, Dueñas R, et al · · 2015 · cited 14× · PMID 25752908 · DOI 10.1007/s11523-015-0362-0
Verify or expand the search:
- PubMed search for NCT01493713
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colorectal Cancer
Currently open trials in the same condition.
- NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
- NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting
Other Grupo Espanol Multidisciplinario del Cancer Digestivo trials
Trials by the same sponsor.
- NCT04293419 — Durvalumab (MEDI4736) Plus Total Neoadjuvant Therapy (TNT) in Locally Advanced Rectal Cancer · Phase 2 · unknown
- NCT03751176 — Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal · Phase 2 · unknown
- NCT03152565 — Avelumab Plus Autologous Dendritic Cell Vaccine in Pre-treated Metastatic Colorectal Cancer Patients · Phase 1, PHASE2 · completed
- NCT03142516 — FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF · Phase 2 · completed
- NCT03000374 — Induction Therapy With Panitumumab + mFOLFOX-6 in Rectal Cancer and Quadruple Wild-type Mutation Before Surgery · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01493713 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Grupo Espanol Multidisciplinario del Cancer Digestivo
- Last refreshed: 19 February 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01493713.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing